Comparing Haemophilus influenzae Type b Conjugate Vaccine Schedules

Low, Nicola; Redmond, Shelagh; Rutjes, Anne W S; Martínez-González, Nahara Anani; Egger, Matthias; Nisio, Marcello Di; Scott, Pippa

doi:10.1097/inf.0b013e31829f0a7e

Cited by 13 publications

(6 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Any combination of 2p+1, 3p+0, or 3p+1 schedule of Hib conjugate vaccine has no inferiority to another type. The selection of each program is based on the epidemiology of the infectious organism and is individualized (22). GMT titer against H flu type B in this study was 6.92 (CI: 6.76 -7.08), six cases had a level of less than 0.15 µg/mL, and approximately 50% of the children had a level of less than 1 µg/mL.…”

Section: Discussionmentioning

confidence: 76%

Study of Serologic Response Rate to Haemophilus influenzae Type B After Administration of the Third Dose of Pentavalent Vaccine in Children Aged 12 Months in Karaj City in 2016

Arjmand¹,

Gholami

Shirvani

et al. 2018

Arch Clin Infect Dis

View full text Add to dashboard Cite

Background: Hib conjugate vaccine has led to more than 90% decline in the prevalence of severe Hib diseases in countries with universal coverage vaccination program. After the addition of Hib vaccine to the national vaccination program with 3P (three doses of 2, 4, and 6 months) in IR Iran, we decided to study the vaccine efficacy after the last dose of vaccine in Iranian children in 2016. Methods: 500 blood samples were collected from one-year-old children who referred to the health care centers in Karaj. Demographic information was gathered by a questionnaire. Blood samples were sent to a laboratory for antibody titer determination by ELISA method. Results: 41.2% of the children (95% CI: 36.89-45.51) had a titre of IgG against Hib (0.15 to 1 µg/mL) (short-term protection) and 57.4% of the children had a titre of IgG against Hib (95% CI: 53.07-61.73) equal to or greater than 1 µg/mL (long-term protection). Antibody GMT was 6.92 µg/mL (95% CI: 6.76-7.08). There was no significant correlation between the titer of H. influaenza antibody and demographic factors. Conclusions: In spite of the acceptable GMT titer, children who had antibody titer of < 1 µg/mL comprised approximately 40% of the study population, showing the necessity of further investigation to assess the need for H.flu booster administration.

show abstract

Section: Discussionmentioning

confidence: 76%

Study of Serologic Response Rate to Haemophilus influenzae Type B After Administration of the Third Dose of Pentavalent Vaccine in Children Aged 12 Months in Karaj City in 2016

Arjmand¹,

Gholami

Shirvani

et al. 2018

Arch Clin Infect Dis

View full text Add to dashboard Cite

show abstract

“…A meta-analysis of 20 RCTs, which had been conducted in 15 countries (United States, Canada, Chile, Guatemala, Belgium, Austria, Germany, Greece, France, Sweden, Netherlands, Turkey, The Gambia, Niger, China) compared different Hib vaccination schedules (3 1 0, 3 1 1, and 2 1 1) and different intervals between the primary schedule and the primary and booster dose schedule (184). There was no difference between the schedules in terms of prevention of invasive Hib disease, clinical effectiveness, or immunologic response.…”

Section: Is a Booster Dose Of Hib Vaccine Needed?mentioning

confidence: 99%

Invasive Haemophilus influenzae Infections after 3 Decades of Hib Protein Conjugate Vaccine Use

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Where the burden of infection occurs at a later age, the third dose could be given in the second year of life. In countries like the UK, where Hib infections resurged with a 3 + 0 schedule, a booster in the second year of life may be required [ 99 ]. Children who are HIV infected may require a booster dose of vaccine [ 100 ].…”

Section: Resurgence Of Hib Meningitis In Some Countriesmentioning

confidence: 99%

Long Term Impact of Conjugate Vaccines on Haemophilus influenzae Meningitis: Narrative Review

Slack

2021

Microorganisms

View full text Add to dashboard Cite

H. influenzae serotype b (Hib) used to be the commonest cause of bacterial meningitis in young children. The widespread use of Hib conjugate vaccine has profoundly altered the epidemiology of H. influenzae meningitis. This short review reports on the spectrum of H. influenzae meningitis thirty years after Hib conjugate vaccine was first introduced into a National Immunization Program (NIP). Hib meningitis is now uncommon, but meningitis caused by other capsulated serotypes of H. influenzae and non-typeable strains (NTHi) should be considered. H. influenzae serotype a (Hia) has emerged as a significant cause of meningitis in Indigenous children in North America, which may necessitate a Hia conjugate vaccine. Cases of Hie, Hif, and NTHi meningitis are predominantly seen in young children and less common in older age groups. This short review reports on the spectrum of H. influenzae meningitis thirty years after Hib conjugate vaccine was first introduced into a NIP.

show abstract

Comparing Haemophilus influenzae Type b Conjugate Vaccine Schedules

Cited by 13 publications

References 50 publications

Study of Serologic Response Rate to Haemophilus influenzae Type B After Administration of the Third Dose of Pentavalent Vaccine in Children Aged 12 Months in Karaj City in 2016

Study of Serologic Response Rate to Haemophilus influenzae Type B After Administration of the Third Dose of Pentavalent Vaccine in Children Aged 12 Months in Karaj City in 2016

Invasive Haemophilus influenzae Infections after 3 Decades of Hib Protein Conjugate Vaccine Use

Long Term Impact of Conjugate Vaccines on Haemophilus influenzae Meningitis: Narrative Review

Contact Info

Product

Resources

About